ongestive heart failure (CHF) is the final phase of cardiovascular disease and has high morbidity and mortality. Sleep-related breathing disorders are fairly common in patients with CHF. Intermittent apnea-induced hypoxia, hypercapnia, surges in central sympathetic outflow and loss of vagal heart rate regulation are potent stimuli for myocyte necrosis and apoptosis, myocardial ischemia, adverse cardiac remodeling, and accelerated disease progression in CHF, ultimately contributing to increased mortality. 1 Treating sleep apnea (SA) with positive pressure ventilation (PPV) in patients with CHF is a widely applicable, novel approach for CHF. 2, 3 Amino terminal-pro brain natriuretic peptide (NT-proBNP) is a useful indicator for treatment effectiveness in CHF, 4, 5 so the objective of this study was to assess the short-term effect of PPV on the plasma levels of NT-proBNP in patients with CHF and SA.
Methods
One hundred and five CHF patients were consecutively recruited from the Cardiology Department of Fu-Wai Heart Hospital (81 males, 24 females; 55±12 years). The inclusion criterion was CHF classified as New York Heart Association (NYHA) Class II-IV. Patients were excluded from the study as described previously. 6 The criterion for PPV treatment was CHF patients diagnosed with SA by sleep study who could be followed up for 2-15 days. The study was approved by the Science and Ethics Committee of FuWai Heart Hospital.
All patients underwent overnight (from 22.00 h to 05.00 h) polysomnography with an automated system (Embletta 9 or Monet-11, Medcare). Apnea, central apnea (CSA), obstructive apnea (OSA), and hypopnea were defined as described previously. 7 We accepted a threshold apnea -hypopnea index (AHI) ≥10 /h as diagnostic of SA. Twenty-six patients in the group with SA were randomly assigned to a control group (optimal drug therapy) or a PPV group (optimal drug therapy + PPV; 7.3±1 h/night; mean pressure or mean inspiratory pressure 12.2±2.3 cmH2O). OSA patients received auto-continuous positive airway pressure (auto-CPAP; ResMed Corp), and CSA patients received adaptive pressure support servo-ventilation (ASV; ResMed Corp). Venous blood samples were obtained in the early morning (05.00 h), and the plasma NT-proBNP levels were measured using an enzyme immunoassay kit (BIOMEDICA, GmbH, Germany).
All descriptive data are presented as mean ± SD. Continuous variables with skewed distributions were natural logtransformed to obtain a better approximation of a normal distribution. The differences of means between 2 groups were analyzed by the independent samples t-test. One-way ANOVA was used to test for differences among multiple groups. Differences between values at baseline and 6-7 days later were assessed by the paired t-test. Repeated measurements within a generalized linear model were used to test the effect of PPV on plasma NT-proBNP levels. Body mass index and age were adjusted by incorporating them as covariates. A p-value <0.05 was considered statistically significant. Background The purpose of the present study was to assess the short-term effects of positive pressure ventilation (PPV) on plasma amino terminal-pro brain natriuretic peptide (NT-proBNP) levels in patients with congestive heart failure (CHF) and sleep apnea (SA).
Methods and Results
Polysomnography was performed in 105 CHF patients. Twenty-six patients with CHF and SA were randomly assigned to a control group or a PPV group. Patients in the higher New York Heart Association classes had higher plasma levels of NT-proBNP. The plasma NT-proBNP concentration in the PPV group decreased. Table 1 shows the clinical characteristics and plasma levels of NT-proBNP in the 3 groups. In NYHA class II, III and IV patients the plasma NT-proBNP levels were 516.5±573.0 fmol/ml (n=32), 782.2±718.1 fmol/ml (n=29; compared with NYHA class II, p<0.05) and 1,550.9± 1,344.7 fmol/ml (n=44; compared with NYHA class II, p<0.001; compared with NYHA class III, p<0.05), respectively. Table 2 shows the baseline characteristics and changes in the plasma NT-proBNP levels of the PPV and control groups. After an average of 7 days treatment with PPV, the AHI of the PPV group decreased from 39.6±12.7 to 7.2±5.2 (p<0.001), the minimum arterial oxygen saturation (SaO2) increased from 73.3±4.8% to 83.1±3.9% (p<0.001), and the plasma NT-proBNP levels decreased significantly.
Conclusion

Discussion
A retrospective study has shown that obesity is the dominant risk factor for OSA. 7 The remarkable nocturnal hypoxia in CHF patients with SA augments sympathetic activity and aggravates heart dysfunction. 1 Through the combined adverse effects of hypoxia and obesity, SA in patients with CHF suggests a poor prognosis and increased mortality. We demonstrated that the plasma level of NTproBNP is associated with the extent of CHF; that is, patients in higher NYHA classes had higher levels of NTproBNP. Fonseca et al confirmed that both brain natriuretic peptide (BNP) and NT-proBNP had an excellent ability to distinguish patients with CHF from healthy volunteers, and that NT-proBNP was more sensitive and specific. 4 Thus we chose NT-proBNP as the indicator for treatment effectiveness. A large body of evidence shows that NT-proBNP and BNP levels increase with the severity of heart failure. Patients with improving NYHA class have decreasing levels of BNP, whereas patients with clinical deterioration have increasing BNP levels. 5 PPV treatment in CHF patients reduces sympathetic nerve activity, decreases left ventricular afterload, increases cardiac output, alleviates pulmonary congestion, prevents alveolar shrinkage, elevates oxygen saturation, and alleviates the work of breathing. In a randomized trial involving 24 patients with CHF and OSA, continuous positive airway pressure for 1 month reduced daytime heart rate, systolic blood pressure, and increased left ventricular ejection fraction. 8 Furthermore, ASV improves excessive daytime sleepiness in patients with Cheyne-Stokes respiration (CSR) and CHF, as well as reducing plasma BNP and urinary metadrenaline excretion. 9 Kasai et al also demonstrated the efficacy of nasal bi-level positive airway pressure in CHF patients with CSR and CSA. 10 In our study, both auto-CPAP treatment for OSA and ASV treatment for CSA decreased the plasma NT-proBNP levels and increased SaO2, suggesting that PPV treatment can reduce cardiac pressure and volume load. We demonstrated the short-term effect of PPV on the plasma concentration of NT-proBNP in patients with CHF and SA. A follow-up study is warranted to determine the long-term beneficial effects. In terms of CHF treatment, the sample sizes of the control and PPV groups were relatively small, so the results of the present study need to be independently replicated in larger samples.
In conclusion, the plasma concentrations of NT-proBNP reflect the clinical severity of CHF, and short-term PPV treatment decreases the NT-proBNP level.
